- No file added yet -

Cost-Utility Analysis of Nivolumab in the Adjuvant Treatment of Melanoma in France

media

posted on 2020-09-11, 15:40 authored by Bruno Bregman, Siguroli Teitsson, Isabella Orsini, François-Emery Cotté, Adenike Amadi, Andriy Moshyk, Stéphane Roze, Anne-Françoise Gaudin

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).